Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Deep mutational scanning for epitope mapping of antibodies targeting SARS-CoV-2.

PROVIDER: PRJNA835296 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19091579.fastq.gz	Fastqsanger.gz
	SRR19091580.fastq.gz	Fastqsanger.gz
	SRR19091581.fastq.gz	Fastqsanger.gz
	SRR19091582.fastq.gz	Fastqsanger.gz
	SRR19091583.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Severe acute respiratory syndrome coronavirus 2

Project description:Deep mutational scanning of SARS-CoV-2 Spike HR1

| PRJNA826665 | ENA

Project description:Deep mutational scanning of SARS-CoV-2 3CL protease

| PRJNA813935 | ENA

Project description:SARS-CoV-2 spike phage deep mutational scanning to map binding residues of monoclonal antibodies

| PRJNA1122188 | ENA

Project description:SARS-CoV-2 spike phage deep mutational scanning to map binding residues of monoclonal antibodies

| PRJNA1130943 | ENA

Project description:Deep mutational scanning of SARS-CoV-2 spike fusion peptide

| PRJNA910585 | ENA

SARS-CoV-2 pseudovirus strain:BA.2

Project description:SARS-CoV-2 BA.2 spike pseudovirus-based deep mutational scanning

| PRJNA1035933 | ENA

Passive Infusion of an S2-Stem Broadly Neutralizing Antibody protects against SARS-CoV-2 infection and lower airway inflammation

Project description:The continued evolution of SARS-CoV-2 variants capable of subverting vaccine and infection-induced immunity suggests the advantage of a broadly protective vaccine against betacoronaviruses (β-CoVs). Recent studies have isolated monoclonal antibodies (mAbs) from SARS-CoV-2 recovered-vaccinated donors capable of neutralizing many variants of SARS-CoV-2 and other β-CoVs. Many of these mAbs target the conserved S2 stem region of the SARS-CoV-2 spike protein, rather the receptor binding domain contained within S1 primarily targeted by current SARS-CoV-2 vaccines. One of these S2-directed mAbs, CC40.8, has demonstrated protective efficacy in small animal models against SARS-CoV-2 challenge. As the next step in the pre-clinical testing of S2-directed antibodies as a strategy to protect from SARS-CoV-2 infection, we evaluated the in vivo efficacy of CC40.8 in a clinically relevant non-human primate model by conducting passive antibody transfer to rhesus macaques (RM) followed by SARS-CoV-2 challenge. CC40.8 mAb was intravenously infused at 10mg/kg, 1mg/kg, or 0.1 mg/kg into groups (n=6) of RM, alongside one group that received a control antibody (PGT121). Viral loads in the lower airway were significantly reduced in animals receiving higher doses of CC40.8. We observed a significant reduction in inflammatory cytokines and macrophages within the lower airway of animals infused with 10mg/kg and 1mg/kg doses of CC40.8. Viral genome sequencing demonstrated a lack of escape mutations in the CC40.8 epitope. Collectively, these data demonstrate the protective efficiency of broadly neutralizing S2-targeting antibodies against SARS-CoV-2 infection within the lower airway while providing critical preclinical work necessary for the development of pan–β-CoV vaccines.

2024-12-31 | GSE283190 | GEO

Severe acute respiratory syndrome coronavirus 2

Project description:Deep mutational scanning of SARS-CoV-2 Spike N-terminal domain (NTD)

| PRJNA792013 | ENA

Nanobodies agains Sars Cov 2 Nsp9 protein protects cells from virus infection

Project description:Nanobodies are emerging as ideal instruments for drug design and several have recently been created to block SARS-Cov-2 entry in the host cell by targeting surface-exposed Spike protein. However, due to the high frequency of mutations that affect Spike, these nanobodies may not efficiently target Spike during viral entry. Here we have established a pipeline that instead targets highly conserved viral proteins that are made only after viral entry into the host cell when the SARS-Cov-2 RNA-based genome is translated. As proof of principle, we designed nanobodies against the SARS-CoV-2 non-structural protein Nsp9, required for replication of the viral genome. To find out if this strategy efficiently blocked viral replication, one of these anti-Nsp9 nanobodies, 2NSP23, previously characterized using immunoassays and NMR spectroscopy for epitope mapping, was encapsulated into lipid nanoparticles (LNP) as mRNA. We show that this nanobody, hereby referred to as LNP-mRNA-2NSP23, is internalized and translated in HEK293 cells. We next infected HEK293-ACE2 cells subjected to LNP-mRNA-2NSP23 with multiple SARS-CoV-2 variants. Analysis of total RNA isolated form infected cells treated or untreated with LNP-mRNA-2NSP23 using qPCR and RNA deep sequencing shows that the LNP-mRNA-2NSP23 nanobody protects HEK293-ACE2 cells and suppresses replication of several SARS-CoV-2 variants. These observations indicate that following translation, the nanobody 2NSP23 inhibits viral replication by targeting Nsp9 in living cells. We propose that LNP-mRNA-2NSP23 may be translated into an innovative technology to generate novel antiviral drugs highly efficient across coronaviruses.

2023-10-10 | GSE244714 | GEO

SARS-CoV-2 pseudovirus strain:XBB.1.5

Project description:SARS-CoV-2 XBB.1.5 RBD-only pseudovirus based deep mutational scanning libraries

| PRJNA1035795 | ENA